January 7, 2019
JCR Pharmaceuticals has completed patient enrolment in a PIII clinical study of its investigational Hunter syndrome treatment therapeutic enzyme JR-141 (development code) in Japan. JR-141 is being developed by harnessing the company’s proprietary blood-brain-barrier (BBB)-penetrating technology, called J-Brain Cargo. The...read more